Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT

Autor: Fiona Collinson, Kara-Louise Royle, Jayne Swain, Christy Ralph, Anthony Maraveyas, Tim Eisen, Paul Nathan, Robert Jones, David Meads, Tze Min Wah, Adam Martin, Janine Bestall, Christian Kelly-Morland, Christopher Linsley, Jamie Oughton, Kevin Chan, Elisavet Theodoulou, Gustavo Arias-Pinilla, Amy Kwan, Luis Daverede, Catherine Handforth, Sebastian Trainor, Abdulazeez Salawu, Christopher McCabe, Vicky Goh, David Buckley, Jenny Hewison, Walter Gregory, Peter Selby, Julia Brown, Janet Brown

Publikováno v: Health Technology Assessment, Vol 28, Iss 45 (2024)

Background There is interest in using treatment breaks in oncology, to reduce toxicity without compromising efficacy. Trial design A Phase II/III multicentre, open-label, parallel-group, randomised controlled non-inferiority trial assessing treatment

Externí odkaz: https://doaj.org/article/f262d31cdee84d25b7afd7439e0362e7

Iatrogenic ureteric stricture post image guided renal cryoablation in a patient with von hippel-lindau syndrome

Autor: Helen Ng, Vinson Wai-Shun Chan, Jon Cartledge, MB BCh MD FRCSEd(Urol), Michael Kimuli, MB BCh FRCS, Christy Ralph, PhD BMBS BMedSci MA MRCP, Satinder Jagdev, MBChB PhD, Naveen Vasudev, PhD MRCP MBChB BMSc (Hons), Selina Bhattarai, MBBS, MD Pathology, FRCPath, James Lenton, MBChB FRCR, Jonathan Smith, MBChB FRCR, Tze Min Wah, PhD, MBChB, FRCR

Publikováno v: Radiology Case Reports, Vol 16, Iss 8, Pp 1980-1984 (2021)

A 53-year-old lady is known to have Von Hippel-Lindau syndrome with a long history of previous renal cell carcinomas (RCCs) in both kidneys. She was treated by partial nephrectomy for a right peripheral RCC and subsequently image guided radiofrequenc

Externí odkaz: https://doaj.org/article/c8d39978b65d40f4bdd816244f935e4f

Urinothorax following percutaneous image-guided renal cryoablation

Autor: Helen Ng, MBChB, Kaiwen Wang, MBChB, Jon Cartledge, MBChB, MD, FRCSEd (Urol), Chandra Shekhar Biyani, MBChB, FRCS, Christy Ralph, PhD, BMBS, BMedSci, MA, MRCP, Satinder Jagdev, MBChB, PhD, Naveen Vasudev, PhD, MRCP, MBChB, BMSc (Hons), Selina Bhattarai, MBBS, MD Pathology, FRCPath, Bobby, Bhartia, MBChB, FRCR, James Lenton, MBChB, FRCR, Jonathan Smith, MBChB, FRCR, Simon Whiteley, MBBS, FRCA, FFICM, Peter Tcherveniakov, MBChB, FRCS, Tze Min Wah, PhD, MBChB, FRCR

Publikováno v: Radiology Case Reports, Vol 15, Iss 11, Pp 2348-2352 (2020)

A 69-year-old lady with 2 renal cell carcinomas, one sited at the upper pole of her solitary right kidney, underwent percutaneous image-guided cryoablation and developed urinothorax as a complication. This was diagnosed from pleural fluid analysis an

Externí odkaz: https://doaj.org/article/3a4ab27228674f0f9e70fa9d207167f2

Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell Cancer

Autor: Jim Zhong, Ebrahim Palkhi, David L. Buckley, Fiona J. Collinson, Christy Ralph, Satinder Jagdev, Naveen S. Vasudev, Jayne Swain, Janet E. Brown, Tze Min Wah

Publikováno v: Diagnostics, Vol 11, Iss 7, p 1302 (2021)

Objective: To identify dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters predictive of early disease progression in patients with metastatic renal cell cancer (mRCC) treated with anti-angiogenic tyrosine kinase inhibitors (TKI

Externí odkaz: https://doaj.org/article/4d6d2aafbb954842b324eda9760a2653

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

Autor: Janet E Brown, Kara-Louise Royle, Walter Gregory, Christy Ralph, Anthony Maraveyas, Omar Din, Timothy Eisen, Paul Nathan, Tom Powles, Richard Griffiths, Robert Jones, Naveen Vasudev, Matthew Wheater, Abdel Hamid, Tom Waddell, Rhona McMenemin, Poulam Patel, James Larkin, Guy Faust, Adam Martin, Jayne Swain, Janine Bestall, Christopher McCabe, David Meads, Vicky Goh, Tze Min Wah, Julia Brown, Jenny Hewison, Peter Selby, Fiona Collinson, Judith Carser, Gopalakrishnan Srinivasan, Fiona Thistlewaite, Ashraf Azzabi, Mark Beresford, David Farrugia, Marios Decatris, Carys Thomas, Joanna Gale, James McAleer, Alison Clayton, Ekaterini Boleti, Thomas Geldart, Santhanam Sundar, Jason Lester, Nachi Palaniappan, Mohan Hingorani, Khaliq Rehman, Mohammad Khan, Naveed Sarwar, Janine Graham, Alastair Thomson, Narayanan Srihari, Denise Sheehan, Rajaguru Srinivasan, Omar Khan, Andrew Stockdale Jane Worlding, Stergios Boussios, Nicholas Stuart, Carey MacDonald-Smith, Falalu Danwata, Duncan McLaren, Aravindhan Sundaramurthy, Anna Lydon, Sharon Beesley, Kathryn Lees, Mohini Varughese, Emma Gray, Angela Scott, Mark Baxter, Anna Mullard, Pasquale Innominato, Gaurav Kapur, Anil Kumar, Natalie Charnley, Caroline Manetta, Prabir Chakraborti, Prantik Das, Sarah Rudman, Henry Taylor, Christos Mikropoulos, Martin Highley, Dakshinamoorthy Muthukumar, Anjali Zarkar, Roy Vergis, Seshadri Sriprasad, Patryk Brulinski, Amanda Clarke, Richard Osbourne, Melanie Harvey, Renata Dega, Geoffrey Sparrow, Urmila Barthakur, Erica Beaumont, Agnieszka Michael, Emilio Porfiri, Faisal Azam, Ravi Kodavtiganti

Publikováno v: STAR Investigators, Brown, J E, Royle, K-L, Gregory, W, Ralph, C, Maraveyas, A, Din, O, Eisen, T, Nathan, P, Powles, T, Griffiths, R, Jones, R, Vasudev, N, Wheater, M, Hamid, A, Waddell, T, McMenemin, R, Patel, P, Larkin, J, Faust, G, Martin, A, Swain, J, Bestall, J, McCabe, C, Meads, D, Goh, V, Min Wah, T, Brown, J, Hewison, J, Selby, P & Collinson, F 2023, ' Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial ', Lancet Oncology, vol. 24, no. 3, pp. 213-227 . https://doi.org/10.1016/S1470-2045(22)00793-8

Temporary drug treatment cessation might alleviate toxicity without substantially compromising efficacy in patients with cancer. We aimed to determine if a tyrosine kinase inhibitor drug-free interval strategy was non-inferior to a conventional conti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a633cdaf72543d0ca87f46d23005d79
https://doi.org/10.1016/s1470-2045(22)00793-8